Birsfelden, Switzerland

Eugen Boss

This inventor holds 1 USPTO granted patent. Top assignee: Novartis Ag. Active years: 2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eugen Boss. Retrieved from https://idiyas.com/inventor/eugen-boss

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Eugen Boss

Introduction

Eugen Boss is a notable inventor based in Birsfelden, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of protein kinase dependent diseases. His work has led to the development of innovative compounds that hold promise for medical advancements.

Latest Patents

Eugen Boss holds a patent for "Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases." This invention relates to the use of diaryl urea derivatives in the treatment of such diseases. It encompasses methods of use, pharmaceutical preparations, and processes for manufacturing these novel compounds. The patent highlights the potential of these derivatives in treating both human and animal bodies.

Career Highlights

Eugen Boss is associated with Novartis AG, a leading global healthcare company. His role at Novartis has allowed him to work on groundbreaking research and development projects. His expertise in medicinal chemistry has been instrumental in advancing therapeutic options for patients.

Collaborations

Eugen has collaborated with esteemed colleagues such as Andreas Floersheimer and Pascal Furet. These partnerships have fostered a collaborative environment that enhances innovation and accelerates the development of new treatments.

Conclusion

Eugen Boss is a distinguished inventor whose work in diaryl urea derivatives represents a significant advancement in the treatment of protein kinase dependent diseases. His contributions to Novartis AG and collaborations with fellow researchers underscore his commitment to improving healthcare through innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…